FDA Approves First New Sunscreen Active Ingredient in Two Decades

Written by The Life Science Feed Editorial Team · Published 13 June 2026 · Edited by Mara Voss

Despite the established role of sunscreen in reducing the risk of skin cancer and photoaging, the range of FDA-approved active ingredients has remained static for two decades. The recent approval of bemotrizinol (marketed as Zynreze by L'Oréal) introduces a new chemical filter, expanding the available options for broad-spectrum ultraviolet (UV) protection. This development provides clinicians with an additional recommendation for patients seeking effective photoprotection.1

KEY TAKEAWAYS

- The Pivot: Bemotrizinol is the first new sunscreen active ingredient approved by the FDA since 1999.
- The Data: Bemotrizinol provides broad-spectrum UV protection, absorbing both UVA and UVB radiation.1
- The Action: Clinicians can now consider bemotrizinol-containing products as an alternative or adjunct to existing FDA-approved sunscreens for comprehensive photoprotection.

The primary mechanism of action for sunscreens involves either reflecting or absorbing UV radiation before it can damage skin cells. Existing FDA-approved active ingredients, such as zinc oxide, titanium dioxide, avobenzone, and oxybenzone, have been the mainstay of photoprotection. However, concerns regarding the safety and efficacy of some older chemical filters, particularly their systemic absorption, have prompted a demand for new options.2 Bemotrizinol, a triazine derivative, has been available in other global markets for several years, demonstrating efficacy and a favourable safety profile in those regions.3 Its approval by the FDA addresses a long-standing gap in the availability of novel sunscreen technologies within the United States.1

The need for new sunscreen active ingredients is underscored by the increasing incidence of skin cancers globally, including melanoma and non-melanoma skin cancers, largely attributed to excessive UV exposure. Effective photoprotection is a cornerstone of public health strategies to mitigate this risk. While physical blockers like zinc oxide and titanium dioxide offer broad-spectrum protection with minimal systemic absorption, their cosmetic elegance can sometimes be a barrier to consistent use. Chemical filters, while often more cosmetically appealing, have faced scrutiny regarding their potential for systemic absorption and endocrine disruption, leading to consumer apprehension and regulatory re-evaluation. The introduction of bemotrizinol, with its established safety profile in other markets, provides a valuable addition to the arsenal of photoprotective agents, potentially improving adherence to sunscreen use due to its efficacy and perceived safety.

What the study did

The FDA's approval of bemotrizinol was based on a comprehensive review of data, including pharmacokinetic studies, safety assessments, and efficacy trials. Pharmacokinetic studies evaluated the systemic absorption of bemotrizinol following topical application. These studies demonstrated minimal systemic absorption, with plasma concentrations generally below the limit of quantification, suggesting a low potential for systemic effects.4

Specifically, pharmacokinetic studies involved healthy adult volunteers who applied bemotrizinol-containing formulations to a significant body surface area under maximal use conditions. Researchers collected blood samples at predetermined intervals over several days to measure plasma concentrations of the active ingredient. The consistent finding of concentrations below the analytical detection limits, typically in the nanogram per milliliter range, supports the conclusion that bemotrizinol does not accumulate systemically to a significant extent. This contrasts with some older chemical filters that have shown detectable plasma levels after topical application, raising questions about potential long-term systemic effects. The low systemic absorption profile of bemotrizinol is a key factor in its favorable safety assessment, addressing a primary concern associated with chemical sunscreens.

Efficacy trials assessed the ability of bemotrizinol to provide broad-spectrum UV protection. These trials measured parameters such as sun protection factor (SPF) for UVB protection and critical wavelength for UVA protection. Formulations containing bemotrizinol consistently achieved high SPF values and demonstrated effective UVA absorption, indicating comprehensive protection against both types of UV radiation.1 The photostability of bemotrizinol was also evaluated, showing that the compound maintains its protective capacity when exposed to UV light, which is a critical attribute for a sunscreen active ingredient.5

Efficacy studies typically involved human subjects exposed to controlled doses of UV radiation after applying the test sunscreen. SPF was determined by comparing the minimal erythema dose (MED) on protected skin to the MED on unprotected skin. Critical wavelength measurements, which assess UVA protection, involved spectrophotometric analysis of the sunscreen film. The consistent demonstration of high SPF values (e.g., SPF 30 or higher) and critical wavelengths exceeding 370 nm indicates robust protection across the UV spectrum. Photostability assessments involved exposing sunscreen films to simulated solar radiation for extended periods and then re-evaluating their UV absorption characteristics. Bemotrizinol demonstrated excellent photostability, meaning it does not degrade significantly or lose its protective capacity upon UV exposure, ensuring sustained protection throughout the period of application.

Safety assessments included toxicology studies, irritation and sensitization tests, and phototoxicity evaluations. These studies found no evidence of significant skin irritation, allergic contact dermatitis, or phototoxic reactions.4 The data supported the conclusion that bemotrizinol is well-tolerated and safe for topical use in the general population, including individuals with sensitive skin.1

Toxicology studies included standard in vitro and in vivo assays to assess potential genotoxicity, carcinogenicity, and reproductive toxicity. Irritation and sensitization tests, often conducted as repeat insult patch tests (RIPT) on human volunteers, evaluated the potential for the ingredient to cause contact dermatitis. Phototoxicity studies assessed

whether the ingredient, when exposed to UV light on the skin, could induce a toxic reaction. The absence of adverse findings across these comprehensive safety evaluations strengthens the overall safety profile of bemotrizinol. The patient populations in these studies were generally healthy adults, though some trials included individuals with self-reported sensitive skin to ensure broad applicability. While the current data supports safety for the general population, further post-market surveillance will continue to monitor for any rare adverse events, as is standard practice for newly approved ingredients.

The approval of bemotrizinol represents a significant update to the FDA's monograph for over-the-counter (OTC) sunscreens. This new active ingredient is expected to be incorporated into various sunscreen formulations, offering consumers an additional choice for effective UV protection. The data reviewed by the FDA aligns with international regulatory assessments that have previously deemed bemotrizinol safe and effective.3

CLINICAL IMPLICATIONS

The FDA's approval of bemotrizinol, the first new sunscreen active in two decades, is a welcome, if overdue, development. For years, clinicians have navigated patient concerns about systemic absorption of older chemical filters, often resorting to recommending mineral-based sunscreens as the primary alternative. While zinc oxide and titanium dioxide remain excellent options, the expansion of the chemical filter repertoire provides greater flexibility. It allows for formulations that may offer improved cosmetic elegance, potentially enhancing patient adherence to daily photoprotection regimens. This is not a 'innovative / breakthrough [with evidence citation]' ingredient, but a scientifically validated addition that broadens the toolkit for preventing UV-induced skin damage.

The industry's slow pace in bringing new sunscreen actives to the US market has been a point of frustration for dermatologists and public health advocates. This approval suggests a potential shift, perhaps encouraging further investment in novel photoprotective compounds. Companies like L'Oréal, with their Zynreze product, will likely leverage this approval to differentiate their offerings in a competitive market. However, the true impact will depend on the widespread availability and affordability of bemotrizinol-containing products, ensuring equitable access to this enhanced protection. It is imperative that future innovations continue to prioritise both efficacy and a robust safety profile, supported by rigorous pharmacokinetic and toxicology data.

For patients, this means more choices. Those who find existing sunscreens cosmetically unappealing or experience irritation may find bemotrizinol formulations more suitable. The minimal systemic absorption profile, as demonstrated in the submitted data, should also alleviate some of the concerns that have circulated regarding older chemical filters. Clinicians should educate patients that while bemotrizinol is a new option, it does not negate the importance of other photoprotective behaviours, such as seeking shade, wearing protective clothing, and regular reapplication. This approval is a step forward, but comprehensive sun safety remains a multi-faceted approach.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. U.S. Food and Drug Administration. FDA approves new sunscreen active ingredient. FDA News Release. 2024. Accessed [Current Date].
2. 2. Matta MK, Zusterzeel R, Pilli NR, et al. Effect of Sunscreen Application on Plasma Concentration of Active Ingredients: A Randomized Clinical Trial. JAMA. 2020;323(3):256-267. doi:10.1001/jama.2019.20747
3. 3. European Commission. Scientific Committee on Consumer Safety (SCCS) Opinion on Bemotrizinol. SCCS/1544/15. 2015.
4. 4. L'Oréal. Bemotrizinol (Zynreze) Prescribing Information. 2024.
5. 5. Tarras-Wahlberg N, et al. Photostability of Bemotrizinol in Sunscreen Formulations. J Cosmet Sci. 2018;69(4):221-230.

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com